Teacher Retirement System of Texas Has $274,000 Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Teacher Retirement System of Texas raised its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 16.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,568 shares of the specialty pharmaceutical company’s stock after buying an additional 1,363 shares during the quarter. Teacher Retirement System of Texas’ holdings in Collegium Pharmaceutical were worth $274,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in COLL. Intech Investment Management LLC grew its stake in shares of Collegium Pharmaceutical by 593.7% in the fourth quarter. Intech Investment Management LLC now owns 67,132 shares of the specialty pharmaceutical company’s stock valued at $1,923,000 after acquiring an additional 57,455 shares in the last quarter. Tejara Capital Ltd acquired a new stake in Collegium Pharmaceutical in the 4th quarter worth about $825,000. Gallacher Capital Management LLC boosted its holdings in Collegium Pharmaceutical by 3.3% in the 4th quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company’s stock valued at $417,000 after purchasing an additional 470 shares during the period. Royce & Associates LP grew its position in shares of Collegium Pharmaceutical by 11.0% during the 4th quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company’s stock worth $9,728,000 after purchasing an additional 33,674 shares in the last quarter. Finally, Vestcor Inc increased its holdings in shares of Collegium Pharmaceutical by 540.6% during the fourth quarter. Vestcor Inc now owns 16,578 shares of the specialty pharmaceutical company’s stock worth $475,000 after purchasing an additional 13,990 shares during the period.

Collegium Pharmaceutical Price Performance

Shares of COLL stock opened at $29.39 on Wednesday. The business has a fifty day simple moving average of $30.21 and a 200 day simple moving average of $32.29. The company has a market cap of $925.37 million, a P/E ratio of 12.67 and a beta of 0.99. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a twelve month low of $27.28 and a twelve month high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. On average, sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on COLL. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Piper Sandler cut their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. Finally, Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Insider Activity at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 1,949 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $30.00, for a total transaction of $58,470.00. Following the sale, the chief financial officer now owns 177,195 shares of the company’s stock, valued at $5,315,850. This trade represents a 1.09 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the business’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the sale, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. This trade represents a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 109,193 shares of company stock valued at $3,243,594 in the last quarter. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.